EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Role of Apolipoprotein A1 in PPAR Signaling Pathway for Nonalcoholic Fatty Liver Disease

Changxi Chen iD, Hongliang Li iD, Jian Song iD, Cheng Zhang iD, Mengting Li iD, Yushan Mao iD, Aiming Liu iD, Juan Du iD

PPAR Research · 18.02.2022 · 2022 · 1-7

DOI: 10.1155/2022/4709300 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PPAR Research, erschienen am 18.02.2022. Verfasst von Changxi Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang Province 315040, China. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Ningbo, National Key R&D Program of China, Science and Technology Program for Agriculture and Social Development Program of Yinzhou, Ningbo, China.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Peroxisome proliferator-activated receptors (PPARs) have been suggested to play crucial roles in the pathology of NAFLD with a vague understanding of the underlying mechanism. Here, we integrated large-scale literature data and clinical data to explore the potential role of the PPAR-APOA1 signaling pathway in the pathology of NAFLD. First, the signaling pathway connecting PPARs, APOA1, and NAFLD was constructed. Then, we employed clinical data to explore the association between APOA1 levels and NAFLD. In addition, we built the APOA1-driven pathway analysis to explore the potential mechanism of the APOA1-NAFLD association. Pathway analysis showed that APOA1 serves as a hubprotein connecting PPARs and NAFLD through a beneficial modulation of 16 out of 21 NAFLD upstream regulators. Each relationship within the composed pathway was supported by results from multiple previous studies. Clinical data analysis showed that an increase of APOA1 level was associated with a significantly decreased NAFLD prevalence ( χ 2 = 292.109 ; P < 0.001 ). When other confounding factors were adjusted, serum APOA1 level was shown as an independent risk factor for the prevalence of NAFLD ( P value

Autor:innen und Institutionen

  • Department of Gastroenterology, Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang Province 315040, China.
  • Department of Endocrinology, Affiliated Hospital of Medical College of Ningbo University, Ningbo, Zhejiang Province 315020, China.
  • School of Medicine, Ningbo University, Ningbo 315211, China.
  • Department of Gastroenterology, Refine-Chemical Hospital of Zhenhai District, Ningbo, Zhejiang Province 315207, China.

ORCID-Profile: Changxi Chen, Hongliang Li, Jian Song, Cheng Zhang, Mengting Li, Yushan Mao, Aiming Liu, Juan Du

Förderung

  • Natural Science Foundation of Ningbo
  • National Key R&D Program of China
  • Science and Technology Program for Agriculture and Social Development Program of Yinzhou, Ningbo, China

Zitieren

APA

Chen, C., Li, H., Song, J., Zhang, C., Li, M., Mao, Y., Liu, A., & Du, J. (2022). Role of Apolipoprotein A1 in PPAR Signaling Pathway for Nonalcoholic Fatty Liver Disease. PPAR Research, 2022, 1-7. https://doi.org/10.1155/2022/4709300

Vancouver

Chen C, Li H, Song J, Zhang C, Li M, Mao Y, et al. Role of Apolipoprotein A1 in PPAR Signaling Pathway for Nonalcoholic Fatty Liver Disease. PPAR Research. 2022;2022:1-7. doi:10.1155/2022/4709300

BibTeX
@article{Chen2022,
  author = {Chen, Changxi and Li, Hongliang and Song, Jian and Zhang, Cheng and Li, Mengting and Mao, Yushan and Liu, Aiming and Du, Juan},
  title = {Role of Apolipoprotein A1 in PPAR Signaling Pathway for Nonalcoholic Fatty Liver Disease},
  journal = {PPAR Research},
  year = {2022},
  volume = {2022},
  pages = {1--7},
  doi = {10.1155/2022/4709300}
}
Kostenlos starten →